New biomarker predicts anthracycline response
Dr John Bartlett - Professor of Molecular Pathology, Edinburgh University
New biomarker predicts anthracycline response ( Dr John Bartlett - Professor of Molecular Pathology, Edinburgh University )
11 Mar 2009
New genetic modelling improves screening for breast cancer
Dr Kathie Dalessandri - Physician Scientist at the University of California, San...
New genetic modelling improves screening for breast cancer ( Dr Kathie Dalessandri - Physician Scientist at the University of California, San Francisco )
11 Mar 2009
Herceptin Increases event-free survival in locally advanced HER2-postive breast ...
Dr Luca Gianni - Director of Medical Oncology, National Cancer Institute, Milan
Herceptin Increases event-free survival in locally advanced HER2-postive breast cancer ( Dr Luca Gianni - Director of Medical Oncology, National Cancer Institute, Milan )
11 Mar 2009
Zoledronic acid may have anti-tumour properties
Dr Robert Coleman - Professor of Medical Oncology, University of Sheffield
Zoledronic acid may have anti-tumour properties ( Dr Robert Coleman - Professor of Medical Oncology, University of Sheffield )
11 Mar 2009
Hormone supplements reduce death from breast cancer
Sarah Marshall - Epidemiologist, University of California, Irvine
Hormone supplements reduce death from breast cancer ( Sarah Marshall - Epidemiologist, University of California, Irvine )
11 Mar 2009
Breast cancer patients may have better option to reduce oestrogen levels
Dr Stephen Jones - Director of US Oncology Research Inc, Texas
Breast cancer patients may have better option to reduce oestrogen levels ( Dr Stephen Jones - Director of US Oncology Research Inc, Texas )
11 Mar 2009
Use of written forms doubles breast cancer detection rate
Dr William Goodson - Senior Clinical Research Scientist, California Pacific Medi...
Use of written forms doubles breast cancer detection rate ( Dr William Goodson - Senior Clinical Research Scientist, California Pacific Medical Center Research Institute )
11 Mar 2009
Predictive value of HER2 and topoisomerase II alpha in early breast cancer patie...
Dr Angelo Di Leo - Sandro Pitigliani Medical Oncology Unit, Prato Hospital
Predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy ( Dr Angelo Di Leo - Sandro Pitigliani Medical Oncology Unit, Prato Hospital )
9 Mar 2009
Poor prognosis on small, HER2 positive tumours
Dr Ana M. Gonzalez-Angula - Department of Breast Medical Oncology, Department of...
Poor prognosis on small, HER2 positive tumours ( Dr Ana M. Gonzalez-Angula - Department of Breast Medical Oncology, Department of Systems Biology at the University of Texas M.D.  Anderson Cancer Center )
9 Mar 2009
ECCO 15 - ESMO 34 Executive Scientific Programme Committee
ECCO-ESMO Roundtable discussion - Full Version
ECCO 15 - ESMO 34 Executive Scientific Programme Committee ( ECCO-ESMO Roundtable discussion - Full Version )
16 Feb 2009
Prophylactic surgery for BRCA1 and BRCA2 carriers
Dr. William Wood, Chairman of the Department of Surgery, Emory University School...
Prophylactic surgery for BRCA1 and BRCA2 carriers ( Dr. William Wood, Chairman of the Department of Surgery, Emory University School of Medicine )
12 Jan 2009
Various molecular imaging devices for non-invasive assessment of protein functio...
Professor David R. Piwnica-Worms, Director of the Molecular Imaging Center, Wash...
Various molecular imaging devices for non-invasive assessment of protein function and gene-expression pathways ( Professor David R. Piwnica-Worms, Director of the Molecular Imaging Center, Washington University )
12 Jan 2009